Trained as a biochemist (UQAM, 1989), and as a molecular and cellular biologist (U. of Montreal 1996 and Karolinska Institutet, Stockholm, Sweden, 2001), Dr. Patrick Provost is a Full Professor in the Department of Microbiology, Infectious diseases and Immunology at the Faculty of Medicine of Université Laval, and a Researcher at the CHU de Québec Research Center/CHUL Pavilion since 2001. To date, the turning point in his career has been his co-discovery, in 2002, of the ribonuclease Dicer in humans. This enzyme catalyzes the formation of microRNAs (19 to 24 nucleotides long), which are now recognized as key regulators of ~60% of the genes in humans.
His current research aims to improve our understanding of the molecular mechanisms underlying the biogenesis, function and transfer of small non-coding RNAs (e. g. microRNAs) between cells and species through extracellular vesicles (EVs; 0.1-1 µm in diameter) in the context of health, nutrition and disease.
His work has been regularly covered by the media, given their importance and translational nature.
Content and therapeutic applications of extracellular vesicles (EVs) in milk
EVs are released from a wide variety of cells in body fluids, including milk. The analysis of cow’s milk intended for human consumption revealed that it contains a new type of EVs, which carries most of the microRNAs (Benmoussa et al., J. Extracell. Vesicles 2017; PMID: 29904572) and is able to protect their microRNAs from degradation during simulated digestion (i. e. under the biophysical, chemical and biochemical conditions prevailing in the human gastrointestinal tract) (Benmoussa et al., J. Nutr. 2016; PMID: 27708120).
We also determined that these EVs isolated from milk were enriched with anti-inflammatory proteins, such as epidermal growth factor 8 (MFG-E8) (Benmoussa et al., J. Proteomics 2019; PMID: 30153512).
These results prompted us to explore the therapeutic potential of milk EVs under inflammatory conditions affecting the gastrointestinal tract.
A unique model to evaluate the oral transfer of dietary microRNAs
It has long been believed that the genetic material (e. g. microRNAs) in food is rapidly degraded during digestion. However, we have demonstrated that microRNAs in cow’s milk intended for human consumption are bioaccessible, partly due to the protective effects of EVs. The ability of milk EVs to protect their labile cargo of bioactive molecules during digestion opens the way for the possible oral transfer of dietary microRNAs. This possibility will be verified through a unique model, which, combined with advanced techniques and approaches, will allow us to confirm (or invalidate) the oral transfer of milk microRNAs.
A new class of small non-coding RNAs
At the heart of the genetic information that flows through our cells (DNA is transcribed into RNA, which is translated into proteins), small species of RNA that do not code for proteins, such as microRNAs (19 to 24 nucleotides (nt) long), are now recognized as key regulators of gene expression.
Contrary to the current scientific dogma, according to which there is no endogenous RNA shorter than 16 nt that can be biologically relevant, we have serendipitously discovered a 12-nt RNA species capable of competing with microRNA regulation of mRNA translation into proteins in human cells (Plante et al., Front. Genet. 2012; PMID: 22675332).
More extensive and in-depth analyses have enabled us to identify a new class of small non-coding RNAs. Our current research aims to elucidate the biogenesis pathway and effector ribonucleoprotein complexes involved in the role and function of these small non-coding RNAs in human and mouse cells.
- Vingt chercheurs du CRCHU reçoivent près de 9 millions de dollars de subvention des IRSC 2019-07-15
- Des microARN très résistants 2016-12-01
- Une nouvelle piste contre l’arthrite : Des chercheurs de la Faculté de médecine ont découvert une cible thérapeutique intéressante pour mieux traiter cette maladie articulaire 2015-07-06
- Diallo, IdrissaDoctoral studentCHUL+1 418-525-4444, extension 42296Idrissa.Diallo@crchudequebec.ulaval.ca
2705 Boulevard Laurier
Canada G1V 4G2
- Husseini, ZeinabDoctoral firstname.lastname@example.org
- Lambert, MarineDoctoral studentCHUL+1 418-525-4444, extension email@example.comMarine.Lambert@crchudequebec.ulaval.ca
2705, boulevard Laurier
Canada G1V 4G2
Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs.Journal Article
Arterioscler Thromb Vasc Biol, 19 (2), pp. 372-7, 1999, ISSN: 1079-5642.
Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor.Journal Article
Br J Pharmacol, 123 (2), pp. 251-8, 1998, ISSN: 0007-1188.
The antiadhesive and antithrombotic effects of the nitric oxide donor SIN-1 are combined with a decreased vasoconstriction in a porcine model of balloon angioplasty.Journal Article
Arterioscler Thromb Vasc Biol, 17 (9), pp. 1806-12, 1997, ISSN: 1079-5642.
Endothelium-derived nitric oxide decreases polymorphonuclear leukocyte interaction with the deeply injured arterial wall under intermediate and high shear conditions.Journal Article
Thromb Haemost, 78 (2), pp. 939-46, 1997, ISSN: 0340-6245.
Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs.Journal Article
Arterioscler Thromb Vasc Biol, 17 (6), pp. 1185-91, 1997, ISSN: 1079-5642.
Endogenous nitric oxide release modulates mural platelet thrombosis and neutrophil-endothelium interactions under low and high shear conditions.Journal Article
Thromb Res, 85 (4), pp. 315-26, 1997, ISSN: 0049-3848.
BW755C, a dual lipoxygenase/cyclooxygenase inhibitor, reduces mural platelet and neutrophil deposition and vasoconstriction after angioplasty injury in pigs.Journal Article
J Pharmacol Exp Ther, 277 (1), pp. 17-21, 1996, ISSN: 0022-3565.
Increase of neutrophil adhesion and vasoconstriction with platelet deposition after deep arterial injury by angioplasty.Journal Article
Am Heart J, 129 (3), pp. 445-51, 1995, ISSN: 0002-8703.
Sustained myocardial protection by clentiazem (TA-3090) after a 90-minute coronary occlusion and 72 hours of reperfusion in dogs with collateral flow.Journal Article
J Cardiovasc Pharmacol, 22 (2), pp. 264-72, 1993, ISSN: 0160-2446.
- A novel class of small non-coding RNAs, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2019-04-01 to 2024-03-31
- A unique model to assess the oral transfer of dietary microRNAs, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2022-09-30
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31